Drug Profile
LY 3200882
Alternative Names: LY-3200882Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours in Australia (PO)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours in Canada (PO)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours in France (PO)